Cet article décrit la prise en charge des cancers bronchiques à petites cellules de stade localisé. Les modalités du bilan d’extension, de la radiothérapie thoracique, de l’irradiation prophylactique cérébrale y ont présentés. Nous discutons également la place des inhibiteurs de point de contrôle immunitaire, de la chirurgie et de la radiothérapie stéréotaxique thoracique.This article describes the treatment strategies of localized small cell lung cancer. The modalities of pre-therapeutic evaluation, thoracic radiotherapy and prophylactic brain radiotherapy are presented. We discuss also the place of immune checkpoint inhibitor, surgery and thoracic stereotactic radiotherapy
Of all lung cancers, small cell lung cancer ( SCLS ) occurs with frequency of 25 - 30%. Patient with...
The aim of the study is to evaluate the outcome of low-dose bifractionated up-front radiotherapy (RT...
Many major technical developments have occurred during the last decades in radiotherapy: our efficac...
International audienceThis article describes the treatment strategies of localized small cell lung c...
Cet article décrit les avancées récentes relatives à la prise en charge diagnostique et thérapeutiqu...
These updated clinical practice guidelines on the treatment of small cell lung cancer (SCLC) limited...
Girard, NMornex, FFranceCancer Radiother. 2011 Oct;15(6-7):522-6. Epub 2011 Sep 1.National audienceO...
Small-cell lung cancer (SCLC) accounts for 13% of all lung tumors. The standard treatment in patient...
Abstract Small‐cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor that is prone to ...
Purpose: Several sentinel phase III randomized trials have recently been published challenging tradi...
Small cell lung cancer (SCLC) accounts for approximately 20% of all lung cancers. The main treatment...
Key words: Small cd lung cancer. Radiotherapy to chess Radiotherapy variably; Local contrd; Local fa...
Small cell lung cancer is a recalcitrant malignancy with 5-year survival rates of less than 20%. In ...
Thoracic radiation therapy promises both survival and local-regional control benefits to patients, t...
Das Bronchialkarzinom ist heute der häufigste Tumor des Mannes und einer der häufigsten bei der Frau...
Of all lung cancers, small cell lung cancer ( SCLS ) occurs with frequency of 25 - 30%. Patient with...
The aim of the study is to evaluate the outcome of low-dose bifractionated up-front radiotherapy (RT...
Many major technical developments have occurred during the last decades in radiotherapy: our efficac...
International audienceThis article describes the treatment strategies of localized small cell lung c...
Cet article décrit les avancées récentes relatives à la prise en charge diagnostique et thérapeutiqu...
These updated clinical practice guidelines on the treatment of small cell lung cancer (SCLC) limited...
Girard, NMornex, FFranceCancer Radiother. 2011 Oct;15(6-7):522-6. Epub 2011 Sep 1.National audienceO...
Small-cell lung cancer (SCLC) accounts for 13% of all lung tumors. The standard treatment in patient...
Abstract Small‐cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor that is prone to ...
Purpose: Several sentinel phase III randomized trials have recently been published challenging tradi...
Small cell lung cancer (SCLC) accounts for approximately 20% of all lung cancers. The main treatment...
Key words: Small cd lung cancer. Radiotherapy to chess Radiotherapy variably; Local contrd; Local fa...
Small cell lung cancer is a recalcitrant malignancy with 5-year survival rates of less than 20%. In ...
Thoracic radiation therapy promises both survival and local-regional control benefits to patients, t...
Das Bronchialkarzinom ist heute der häufigste Tumor des Mannes und einer der häufigsten bei der Frau...
Of all lung cancers, small cell lung cancer ( SCLS ) occurs with frequency of 25 - 30%. Patient with...
The aim of the study is to evaluate the outcome of low-dose bifractionated up-front radiotherapy (RT...
Many major technical developments have occurred during the last decades in radiotherapy: our efficac...